Unlike most peptides, which bind to a specific GPCR or tyrosine kinase, AOD-9604 acts via several indirect pathways with a predominance of effects on adipocytes (fat cells)
This distinction matters because it affects insurance coverage, labeling, and how the medication is prescribed
Some approved drugs are themselves peptides, such as: Insulin GLP-1 receptor agonists Calcitonin Oxytocin Such success has spurred scientists to look into even more potential therapeutic peptides
Deficiency can lead to fatigue, cognitive impairment, muscle weakness, and other symptoms, making timely diagnosis and treatment critical for overall health
It is designed to support repair signaling, inflammation control, collagen remodeling, and tissue organization
This research received worldwide media attention, including coverage in numerous TV and radio shows, newspapers and blogs